Akari Therapeutics PLC ADR AKTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AKTX is a good fit for your portfolio.
News
-
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
-
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates VIVK, MINM, SDPI, AKTX
-
SHAREHOLDER ALERT: The M&A Class Action Launches Investigation of the Merger – SDPI, MINM, SCX, AKTX
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates VIVK, MINM, SDPI, AKTX
-
Kuehn Law Encourages VIVK, MINM, SDPI, and AKTX Investors to Contact Law Firm
-
INVESTIGATION UPDATE: Halper Sadeh LLC Investigates IGT, AKTX, SDPI, VIVK
-
Kuehn Law Encourages VIVK, HES, SDPI, and AKTX Investors to Contact Law Firm
Trading Information
- Previous Close Price
- $1.19
- Day Range
- $1.17–1.20
- 52-Week Range
- $1.08–5.50
- Bid/Ask
- $1.17 / $1.20
- Market Cap
- $9.43 Mil
- Volume/Avg
- 45 / 11,852
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 12
- Website
- https://www.akaritx.com
Valuation
|
Metric
|
AKTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AKTX
|
|---|---|
Quick Ratio | 0.84 |
Current Ratio | 0.95 |
Interest Coverage | — |
Quick Ratio
AKTX
Profitability
|
Metric
|
AKTX
|
|---|---|
Return on Assets (Normalized) | −179.91% |
Return on Equity (Normalized) | −1,085.22% |
Return on Invested Capital (Normalized) | −1,090.88% |
Return on Assets
AKTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wtvpxrjw | Mxcm | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pjqfcckw | Qhwqmd | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Krwnbvqyr | Kwvxpys | $97.8 Bil | |
MRNA
| Moderna Inc | Nqnjfrhbg | Rncgf | $38.8 Bil | |
ARGX
| argenx SE ADR | Ktkhhglwl | Gmrhx | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Dcpfndlp | Fbkb | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Sgxcgkyh | Slzfxs | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Csphvzyrm | Nvjhd | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Swfjlnvps | Dlnllkn | $12.5 Bil | |
INCY
| Incyte Corp | Wnccmnzxv | Vgtcyyf | $11.5 Bil |